Search results for: Oncology
Filter search results
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…and Simona Bianchi (ABPI). The Cancer Drugs Fund (CDF) was created in 2010 to pay for oncology indications that were not approved by the National Institute for Health and Care…
OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison
5 October 2016
…Evidence Generation Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers Personalised Medicine and the Value of Molecular Diagnostics Governance models for real-world evidence The Expanding Value Footprint of Oncology Treatments Lou…
New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
26 September 2016
…addition, case study analyses revealed significant possible savings, such as the €7.1 billion that could be saved during the period 2016-2020, through increased generic and biosimilar competition in the oncology…
Paula Lorgelly Joins the OHE Team as Deputy Director
4 December 2015
…areas of health economics: the determinants of health, economic evaluation and outcome measurement. Most recently she has been working in the clinical areas of oncology, including genomic testing; maternal mental…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…by use of value-based assessment of health and health-related outcomes and by value-based pricing. Additional incentives may be needed for ultra-orphan drugs in oncology and other diseases. Effective management of…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…patient per indication, and is the necessary data being generated routinely or requiring ad hoc intervention? There is a UK collaboration to pilot, in oncology, the feasibility of MIP in…
OHE Appoints New Deputy Director: Associate Professor Paula Lorgelly
13 August 2015
…research spans three key areas of health economics: the determinants of health, economic evaluation and outcome measurement. She is currently working in the clinical areas of oncology, including genomic testing;…
Do Respondents Completing Abstract, Hypothetical Priority-Setting Exercises Agree with the Policy Implications of Their Choices?
3 March 2015
…Oncology Initiative, examined the impact of alternative presentations of hypothetical priority setting scenarios, and the extent to which the study respondents agreed with the policy implications of their responses to…
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
…decision making. For OHE’s primer on MCDA, click here. 3. The Expanding Value Footprint of Oncology Treatments. Juan Carlos Rejon-Parrilla (OHE), Karla Herandez-Villafuerte (OHE), Koonal K Shah (OHE), Jorge Mestre-Ferrandiz…